The role of platelets in peripheral vascular disease

• Published in: European journal of vascular and endovascular surgery 2003-01, Vol.25 (1), p.6-15
• Main Authors: Cassar, K., Bachoo, P., Brittenden, J.
• Format: Article
• Language: English
• Subjects: Angioplasty; Angioplasty, Balloon - adverse effects; Arteriosclerosis - etiology; Arteriosclerosis - physiopathology; Blood Coagulation; Blood Platelets - physiology; Graft Occlusion, Vascular - etiology; Graft Occlusion, Vascular - physiopathology; Hemostasis - physiology; Humans; Muscle, Smooth, Vascular - physiology; Peripheral vascular diseases; Peripheral Vascular Diseases - blood; Peripheral Vascular Diseases - etiology; Peripheral Vascular Diseases - physiopathology; Platelet Activation; Platelet aggregation; Platelet aggregation inhibitors; Platelet Aggregation Inhibitors - therapeutic use; Platelets; Thrombosis - etiology; Thrombosis - physiopathology
• ISSN: 1078-5884; 1532-2165
• DOI: 10.1053/ejvs.2002.1795

Platelets play a major role in acute ischaemic syndromes and peripheral vascular disease. They are involved in the development and progression of atherosclerosis, native vessel and graft thrombosis. They have a central role in the development of restenosis and reocclusion after peripheral percutaneous transluminal angioplasty. Antiplatelet therapy has been shown to be beneficial in patients undergoing peripheral vascular surgery or radiological intervention. Yet current routine therapy, namely aspirin and dipyridamole are limited in their mode of action and efficacy. Recent developments in the understanding of platelet function has led to the development of new more potent drugs such as clopidogrel. Combination of drugs and more specific investigation of individual platelet function may well result in improved bypass and angioplasty patency rates. The results of proposed large randomised controlled trials on the role and safety of aspirin and clopidogrel are awaited with interest. Given the importance of platelets in peripheral vascular disease highlighted in this review, achieving an optimal safe anti-platelet effect for each patient with peripheral vascular disease should be the target of future research. Eur J Vasc Endovasc Surg 25, 6–15 (2003)